Retatrutide shows even more impressive numbers in clinical trials, averaging 24.2% body weight reduction
Morning injection before a typically light breakfast, with the understanding that lunch and dinner portions may need to be smaller, often works best for this population
This underscores the urgent need for novel therapies that target the underlying mechanisms of DN
Oral and Non-Injectable Therapies The push toward oral small molecules and non-injectable options reflects the need for more accessible, scalable, and patient-friendly treatments
Claudia Guepet, FNP-C , a provider at Rejuvime Medical in Metairie, Louisiana , specializes in medically supervised weight loss and has guided many patients through GLP1based treatment plans